Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer
NCT07690878Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, Cisplatin micelle injection (HA132), disitamab vedotin, enfortumab vedotin and toripalimab in bladder cancer, sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Pathological Complete Response Rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)disitamab vedotinenfortumab vedotintoripalimab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT07690878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07690878.